Market Cap
US$9.4b
Last Updated
2020/01/23 00:49 UTC
Data Sources
Company Financials +
Executive Summary
ICON Public Limited Company, a clinical research organization, provides outsourced development services to the pharmaceutical, biotechnology, and medical device industries in Ireland, rest of Europe, the United States, and internationally.
Rewards
PE ratio (25.3x) is below the Life Sciences industry average (37.4x)
Risk Analysis
No risks detected for ICLR from our risk checks.
Snowflake Analysis
Solid track record with excellent balance sheet.
Similar Companies
Share Price & News
How has ICON's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: ICLR has not had significant price volatility in the past 3 months.
Market Performance
7 Day Return
0.07%
ICLR
1.3%
US Life Sciences
0.6%
US Market
1 Year Return
32.8%
ICLR
30.4%
US Life Sciences
24.6%
US Market
Return vs Industry: ICLR exceeded the US Life Sciences industry which returned 29.9% over the past year.
Return vs Market: ICLR exceeded the US Market which returned 24.7% over the past year.
Shareholder returns
| ICLR | Industry | Market | |
|---|---|---|---|
| 7 Day | 0.07% | 1.3% | 0.6% |
| 30 Day | 2.8% | 2.9% | 3.0% |
| 90 Day | 17.7% | 16.2% | 10.6% |
| 1 Year | 32.8%32.8% | 30.7%30.4% | 27.3%24.6% |
| 3 Year | 115.6%115.6% | 111.4%110.0% | 50.5%40.8% |
| 5 Year | 207.5%207.5% | 141.9%138.6% | 78.9%59.1% |
Price Volatility Vs. Market
How volatile is ICON's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 week ago | Simply Wall St
Is ICON Public Limited Company (NASDAQ:ICLR) A High Quality Stock To Own?3 weeks ago | Simply Wall St
Is ICON Public Limited Company's (NASDAQ:ICLR) CEO Paid Enough Relative To Peers?1 month ago | Simply Wall St
Does ICON Public Limited Company (NASDAQ:ICLR) Have A Good P/E Ratio?Valuation
Is ICON undervalued compared to its fair value and its price relative to the market?
26.13x
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: ICLR ($169.54) is trading above our estimate of fair value ($133.65)
Significantly Below Fair Value: ICLR is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: ICLR is good value based on its PE Ratio (25.3x) compared to the Life Sciences industry average (37.4x).
PE vs Market: ICLR is poor value based on its PE Ratio (25.3x) compared to the US market (18.9x).
Price to Earnings Growth Ratio
PEG Ratio: ICLR is poor value based on its PEG Ratio (2.7x)
Price to Book Ratio
PB vs Industry: ICLR is overvalued based on its PB Ratio (6.1x) compared to the US Life Sciences industry average (5.3x).
Next Steps
Future Growth
How is ICON forecast to perform in the next 1 to 3 years based on estimates from 15 analysts?
9.2%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: ICLR's forecast earnings growth (9.2% per year) is above the savings rate (1.7%).
Earnings vs Market: ICLR's earnings (9.2% per year) are forecast to grow slower than the US market (14.3% per year).
High Growth Earnings: ICLR's earnings are forecast to grow, but not significantly.
Revenue vs Market: ICLR's revenue (6.9% per year) is forecast to grow slower than the US market (7.5% per year).
High Growth Revenue: ICLR's revenue (6.9% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: ICLR's Return on Equity is forecast to be high in 3 years time (28.4%)
Next Steps
Past Performance
How has ICON performed over the past 5 years?
13.1%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: ICLR has high quality earnings.
Growing Profit Margin: ICLR's current net profit margins (13.1%) are higher than last year (12.9%).
Past Earnings Growth Analysis
Earnings Trend: ICLR's earnings have grown by 13.1% per year over the past 5 years.
Accelerating Growth: ICLR's earnings growth over the past year (18.4%) exceeds its 5-year average (13.1% per year).
Earnings vs Industry: ICLR earnings growth over the past year (18.4%) underperformed the Life Sciences industry 34.6%.
Return on Equity
High ROE: ICLR's Return on Equity (23.7%) is considered high.
Return on Assets
Return on Capital Employed
Next Steps
Financial Health
How is ICON's financial position?
Financial Position Analysis
Short Term Liabilities: ICLR's short term assets ($1.5B) exceed its short term liabilities ($729.0M).
Long Term Liabilities: ICLR's short term assets ($1.5B) exceed its long term liabilities ($479.1M).
Debt to Equity History and Analysis
Debt Level: ICLR's debt to equity ratio (22.7%) is considered satisfactory.
Reducing Debt: Insufficient data to determine if ICLR's debt to equity ratio has reduced over the past 5 years.
Debt Coverage: ICLR's debt is well covered by operating cash flow (97%).
Interest Coverage: ICLR's interest payments on its debt are well covered by EBIT (68.1x coverage).
Balance Sheet
Inventory Level: ICLR has a low level of unsold assets or inventory.
Debt Coverage by Assets: ICLR's debt is covered by short term assets (assets are 4.2x debt).
Next Steps
Dividend
What is ICON's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Current dividend yield vs market & industry
Notable Dividend: Unable to evaluate ICLR's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate ICLR's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if ICLR's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if ICLR's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of ICLR's dividend in 3 years as they are not forecast to pay a notable one for the US market.
Next Steps
Management
What is the CEO of ICON's salary, the management and board of directors tenure and is there insider trading?
3.5yrs
Average management tenure
CEO
Steve Cutler (59yo)
2.8yrs
Tenure
US$7,860,000
Compensation
Dr. Steven A. Cutler, also known as Steve, Ph.D., MBA, has been the Chief Executive Officer of ICON Public Limited Company since March 01, 2017, Dr. Cutler is the Chief Operating Officer of ICON at ICON C ...
CEO Compensation Analysis
Compensation vs Market: Steve's total compensation ($USD7.86M) is about average for companies of similar size in the US market ($USD6.46M).
Compensation vs Earnings: Steve's compensation has been consistent with company performance over the past year.
Management Age and Tenure
3.5yrs
Average Tenure
48yo
Average Age
Experienced Management: ICLR's management team is considered experienced (3.5 years average tenure).
Board Age and Tenure
3.5yrs
Average Tenure
59.5yo
Average Age
Experienced Board: ICLR's board of directors are considered experienced (3.5 years average tenure).
Insider Trading
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Ownership Breakdown
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Management Team
Simon Holmes (52yo)
Executive Vice President of Investor Relations & Corporate Development
- Tenure: 7.3yrs
Dana Poff
Executive Vice President of Program Management
- Tenure: 1yrs
Tom O'Leary
Chief Information Officer
Niamh Murphy
Director of Corporate Communications
Gary Curtis
Senior Vice President of Global Clinical Pharmacology
- Tenure: 10.8yrs
Steve Cutler (59yo)
CEO & Director
- Tenure: 2.8yrs
- Compensation: US$7.86m
Diarmaid Cunningham (44yo)
Chief Administrative Officer
- Tenure: 3.5yrs
Brendan Brennan (40yo)
Chief Financial Officer
- Tenure: 7.9yrs
- Compensation: US$2.55m
Joe Cronin
Chief Human Resources Officer
- Tenure: 3.5yrs
Jonathan Curtain
Vice President of Corporate Finance & Investor Relations
Board Members
Mary Pendergast (68yo)
Non-Executive Director
- Tenure: 5.9yrs
- Compensation: US$355.00k
John Climax (66yo)
Founder & Non-Executive Director
- Tenure: 10yrs
- Compensation: US$344.00k
Eugene McCague (60yo)
Non-Executive Director
- Tenure: 2.3yrs
- Compensation: US$206.00k
Ciaran Murray (56yo)
Non-Executive Chairman of the Board
- Tenure: 2.8yrs
- Compensation: US$3.07m
Billy Hall (70yo)
Non-Executive Director
- Tenure: 6.9yrs
- Compensation: US$385.00k
Steve Cutler (59yo)
CEO & Director
- Tenure: 2.8yrs
- Compensation: US$7.86m
Ronan Murphy (61yo)
Lead Independent Director
- Tenure: 1yrs
- Compensation: US$275.00k
Joan Garahy (56yo)
Non-Executive Director
- Tenure: 2.2yrs
- Compensation: US$206.00k
Hugh Brady (59yo)
Non-Executive Director
- Tenure: 5.8yrs
- Compensation: US$350.00k
Julie O'Neill (52yo)
Non-Executive Director
- Tenure: 0.5yrs
Company Information
ICON Public Limited Company's company bio, employee growth, exchange listings and data sources
Key Information
- Name: ICON Public Limited Company
- Ticker: ICLR
- Exchange: NasdaqGS
- Founded: 1990
- Industry: Life Sciences Tools and Services
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$9.401b
- Shares outstanding: 53.64m
- Website: https://www.iconplc.com
Number of Employees
Location
- ICON Public Limited Company
- South County Business Park
- Leopardstown
- Dublin
- Co. Dublin
- 18
- Ireland
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| IJF | DB (Deutsche Boerse AG) | Yes | Ordinary Shares | DE | EUR | May 1998 |
| ICLR | NasdaqGS (Nasdaq Global Select) | Yes | Ordinary Shares | US | USD | May 1998 |
Biography
ICON Public Limited Company, a clinical research organization, provides outsourced development services to the pharmaceutical, biotechnology, and medical device industries in Ireland, rest of Europe, the United States, and internationally. It specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. The company’s clinical development services include product development planning, strategic consulting, study protocol preparation, clinical pharmacology, pharmacokinetic and pharmacodynamic analysis, site feasibility, patient recruitment and retention, digital patient and site, project management, clinical operations/monitoring, patient centric monitoring, data management, and adaptive and virtual trial services. Its clinical development services also comprise medical imaging, biostatistics, medical affairs, pharmacovigilance, strategic regulatory, electronic endpoint adjudication, medical writing and publishing, interactive response technologies, functional, strategic resourcing central laboratory, bioanalytical laboratory, biomarket development, strategy and analytics, late phase research, patient centered science, and medical device and diagnostics research services, as well as access, commercialization, and communication services, and research trials for us government agencies. The company was founded in 1990 and is headquartered in Dublin, Ireland.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2020/01/23 00:49 |
| End of Day Share Price | 2020/01/22 00:00 |
| Earnings | 2019/09/30 |
| Annual Earnings | 2018/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.